期刊文献+

非劣效国际多中心临床试验中的一致性评价

下载PDF
导出
摘要 目的探讨非劣效国际多中心临床试验中的一致性评价问题,为设计非劣效国际多中心临床试验提供参考。方法我们提出了调整检验水准、基于μ_(all)构造距离比值和基于μ_(all)构造距离比值3种一致性评价方法,并采用蒙特卡罗模拟非劣效临床数据,比较不同参数变化对一致性概率的影响。结果三种方法中,检验水准、比例、设定的处理效应的增大,界值减小,都会使一致性概率增大。结论在试验设计阶段,三种方法均可提供有用的参考,三种方法有各自的优缺点,可依据具体情况选择合适的方法。
出处 《中国卫生统计》 CSCD 北大核心 2017年第6期915-918,共4页 Chinese Journal of Health Statistics
基金 国家自然科学基金(81302512 81773554)
  • 相关文献

参考文献2

二级参考文献18

  • 1Liu JP, Chow SC. Bridging studies in clinical development. J Biop- harm Stat,2002,12(3) :359-367.
  • 2International Conference on Harmonisation;guidance on ethnic factors in the acceptability of foreign clinical data;availability-FDA. Notice. Fed Regist, 1998,63( 111 ) :31790-31796.
  • 3Ando Y, Hamasaki T. Practical issues and lessons learned from multi- regional clinical trials via case examples: a Japanese perspective. Pharm Star,2010,9(3 ) : 190-200.
  • 4Ministry Of Health LAWO and Japan, Basic Principles on Global Clinical Trials. 2007.
  • 5Quan H, et al. Sample size considerations for Japanese patients in a multi-regional trial based on MHLW guidance. Pharm Stat, 2010,9 (2) :100-112.
  • 6Chen X, et al. Decision rules and associated sample size planning for regional approval utilizing multiregional clinical trials. J Biopharm Stat,2012,22 ( 5 ) : 1001-118.
  • 7Huang Q, et al. Design and sample size considerations for simultane- ous global drug development program. J Biopharm Stat,2012,22 (5) : 1060-1073.
  • 8Shein-Chung Chow. Sample Size Calculations in Clinical Research. Second Edition. 2008, Chapman & Hall/CRC.
  • 9Shih WJ. Clinical trials for drug registrations in Asian-Pacific coun- tries:proposal for a new paradigm from a statistical perspective. Con- trol Clin Trials,2001,22(4) :357-366.
  • 10Gupta, S K. Implications of ICH-E5 :Assessment of drug's sensitivity to ethnic factors and necessity of a bridging study for global dmg de- velopment. Perspect Clin Res, 2011,2 ( 4 ) : 121 - 123.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部